Link Lives - Funded by Innovation Fund Denmark, the Link Lives project will collect historical disease data on the majority of families residing in Denmark from 1787 to 1968, which was the year the Civil Registration System was introduced. They will subsequently analyse and compare the old data from before 1968 with new data. This way, the researchers hope to gain insight into disease patterns and be able to identify correlations across generations, for example in connection with deaths due to cancer.
PM-Heart - Funded by Nordforsk/Innovation Fund Denmark, the PM-Heart project will develop and clinically implement personalized medicine (PM) with the dual purpose of avoiding futile overtreatment as well as undertreatment in ischemic heart disease (IHD). Being a Nordic collaboration the project will make it feasible to target this heterogeneous patient group and make it possible to cross-validate and benchmark the results in a new and unprecedented, robust manner.
BIOMAP - Funded by H2020, the BIOMAP project will address three main unmet needs in common chronic inflammatory skin diseases (AD and Pso) with a broad impact on disease management, patient-directed care strategies and future trial designs.
NNF Challenge Grant - Funded by the Novo Nordisk Foundation Challenge Programme: Big Data in Biomedicine. The project, 'Big life-course data analytics for understanding disease initiation and progression in diabetes and its complications' focuses on longitudinal data analysis, which is essential to relate patient trajectories covering many subsequent illnesses to biomarker data from the omics domain.
EU-STANDS4PM - Funded by H2020, the EU-STANDS4PM project will establish a pan-European Expert forum with two main objectives: (i) to assess and evaluate national standardization strategies for interoperable health data integration as well as data-driven in silico modelling approaches and (ii) to harmonize and develop universal (cross-border) standards as well as recommendations for in silico methodologies
applied in personalized medicine approaches.
ImmunAID - Funded by H2020, the ImmunAID project will deliver a method for rapid and accurate diagnosis across all the spectrum of SAID (Systemic autoinflammatory diseases) in order to improve clinical management of patients. Thanks to parallel analyses run on samples from patients collected throughout Europe, ImmunAID will generate a unique and comprehensive set of data, based on unbiased multiomics approaches, and hypothesis-driven assays exploring inflammasome, inflammation resolution and immune networks.
BigTempHealth - The Innovation Fund Denmark has granted money for the BigTempHealth project, which develops methods for analyzing patient record data with focus on extraction of Adverse Drug Reactions from medicine usage. The Danish patient journals and registers describe temporal patient progress. They provide information about millions of Danes, including which pharmaceuticals are given, blood sample analyses and journal text, for describing the adverse drug events. The BigTempHealth project uses data from hospitals in Region Zealand and the Capital Region and the National Patient Register.
DIRECT * - DIabetes REsearCh on patient straTification is a pan-European consortium on pre-competitive research under the Innovative Medicines Initiative (IMI). The aims of DIRECT are to identify biomarkers and define subtypes with rapid diabetes development and progression as well as altered response to diabetes treatment. Additionally, the main goals include identification, development and use of surrogate response biomarkers that reflect the underlying disease progression in clinical trials. For more: http://www.direct-diabetes.org/.
EU-ToxRisk - In a large (€ 30 million) H2020-supported collaborative project, academia joins forces with small and medium-sized enterprises (SMEs), large industry, contract research organizations (CROs) and regulatory bodies to achieve a paradigm shift in toxicology towards a more efficient and animal-free chemical safety assessment. For more information: http://www.eu-toxrisk.eu/.
IDG KMC - Illuminating the Druggable Genome (IDG): collaboration with several US and EU universities. The goal of the IDG Program is to improve our understanding of the properties and functions of proteins that are currently unannotated within the four most commonly drug-targeted protein families: the G-protein coupled receptors, nuclear receptors, ion channels, and protein kinases. The Brunak group is part of the Knowledge Management Center that focuses on cataloging known information.
MedBioinformatics - The MedBioinformatics (H2020) project aims to develop integrative bioinformatics tools and software applications for analyzing the huge amount of data generated in biomedical and healthcare research. The Brunak group’s main contribution is to develop the Disease Comorbidity Trajectory Browser that lets the user browse through trajectories of disease progression mined from 21 years of data covering 6.9 million Danes.
RHAPSODY - The goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, inform clinical trial design, and the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment.
RIMMI - "Regional Immune Modulation of Mucosal Inflammation”. The project aims to take a targeted, systems biology approach to identify novel tissue specific signaling pathways that regulate mucosal adaptive immune responses in homeostasis and inflammation, with a primary focus on the gastrointestinal.
ActionableBiomarkersDK - Danish Infrastructure for Storing and Updating Actionable Biomarkers in Human Disease. The infrastructure addresses the important problem of turning a complete genome into a small set of actionable biomarkers that can be used in diagnostics, in dosage calibration of drugs and in the context of drug development. A data management problem is that biomarker information grows significantly over time and that it resides in many different repositories world-wide in a fragmented way. This project aims to offer a comprehensive solution to this problem, to avoid duplication of effort and to build competence and capacity in this cross-disciplinary field at the interface between biology, genetics, biotechnology, bioinformatics and high performance computing. The project is funded by DeIC (Danish e-Infrastructure Cooperation).
ROADMAP - ‘Real world Outcomes across the AD spectrum for better care: Multi modal data Access Platform’. The ROADMAP project provides the foundation for an integrated data environment and framework for real-world evidence (RWE) in Alzheimer’s disease. This includes the development of consensual key outcome measures and data integration tools for dataset characterization and outcome classification, as well as guidelines on the handling and interpretation of RWE data. ROADMAP is a project under the Innovative Medicines Initiative (IMI) and has a budget of € 7.77 million and 26 partners led by the University of Oxford and Novartis. For more information: https://roadmap-alzheimer.org/.
INNODIA – ‘an INNOovative approach towards understanding and arresting Type 1 DIAbetes’. INNODIA is an international consortium with the overall objective to advance in a decisive way how we predict, evaluate and prevent the onset and progression of type 1 diabetes (T1D), by creating novel tools, such as biomarkers, disease models and clinical trial paradigms. It is a consortium under the Innovative Medicines Initiative (IMI), and consists of 26 academic institutions and clinics, 4 industrial partners (EFPIA), 2 patient organizations and one SME.
Danish NGS – ‘DANISH Next Generation Sequencing and Bioinformatics Platform for Precision Medicine’. The Danish National Advanced Technology Foundation has granted money for the project Danish NGS, which focuses on developing novel prognostic and/or predictive tests that can exploit individual tumor variation to guide treatment decision with regard to a specific underserved disease, Colorectal Cancer.
COST POSTIVe – the initiative ‘an European Concerted research Action: Interindividual variation in response to consumption of plant food bioactives and determinants involved’ combats the burden of cardiometabolic disease by develop efficient strategies that target the dietary behaviors of European consumers and improve the food supply by addressing the inter-individual variation in bioavailability and physiological responses to consumption of plant food bioactives in relation to cardiometabolic endpoints. For more information: https://www6.inra.fr/cost-positive.
NIASC – ‘Nordic Information for Action eScience Centre’. Nordic Centre of Excellence granted money to the project NIASC. The aim of NIASC is to develop databased tools that can provide an overview of biobanks in the Nordic countries and make it possible that data from the national health registries and biobanks can be used better in the health care sector.
Tryggve 2.0* – Tryggve 2.0 is a continuation of the Tryggve project. The project continues to work on developing use of secure cloud capabilities and cross-border data transfers in the pursuit of finding the causes for diseases as well as diagnosing and curing them. The governing partners of Tryggve2 are NeIC and the ELIXIR Nodes in Denmark, Finland (CSC), Norway and Sweden.
ELIXIR* - ELIXIR is an intergovernmental organization that brings together life science resources from across Europe. These resources include databases, software tools, training materials, cloud storage and supercomputers. The goal of ELIXIR is to coordinate these resources so that they form a single infrastructure. This infrastructure makes it easier for scientists to find and share data, exchange expertise, and agree on best practices. Ultimately, it will help them gain new insights into how living organisms work. ELIXIR includes 21 members and over 180 research organizations. ELIXIR participates in several EU-funded projects to drive the delivery of various bioinformatics services to the scientific community. Of these EU-funded projects, the Danish ELIXIR node is participating in eTRANSAFE and EXCELERATE (see below). For more information: https://www.elixir-europe.org/.
eTRANSAFE* - The eTRANSAFE project aims to “Enhance TRANslational SAFEty” assessment through integrative knowledge management of the drug discovery process. A consortium of 26 organizations funded by the Innovative Medicines Initiative (IMI), eTRANSAFE will work towards the establishment of overarching policies and guidelines for data sharing, secondary use of human safety data and use of pooled data and models in drug safety assessment. ELIXIR will as part of eTRANSAFE be leading two main tasks: (1) creating a policy framework that allows industry and other organizations to share drug safety data and adhere to consistent guidelines for predictive toxicology models, and (2) data interoperability and integration. For more information: http://www.etransafe.eu.
EXCELERATE* - EXCELERATE is a €19 million H2020 project to help ELIXIR coordinate and extend national and international data resources and ensure the delivery of world-leading life-science data services. It supports a pan-European training program, anchored in national infrastructures, to increase bioinformatics capacity and competency. Coordinated by the ELIXIR Hub, it involves 46 partners from 17 countries. For more information: www.elixir-europe.org/excelerate.
* Projects at the Technical University of Denmark with collaborative links to the University of Copenhagen Brunak Group.
- Novo Nordisk Fonden
- EU H2020